Table 2.
Morbidity and mortality outcomes following open isolated TVSx
| Cumulative incidence, n (%) | 30 days | 180 days | 2 years | End of study* |
| Congestive cardiac failure | 11 (2.0) | 53 (9.9) | 109 (20.2) | 157 (29.2) |
| Atrial fibrillation† | 10 (4.0) | 25 (10.1) | 40 (16.1) | 68 (27.4) |
| Infective endocarditis† | 4 (0.9) | 7 (1.5) | 10 (2.1) | 26 (5.6) |
| Pulmonary embolism | 1 (0.2) | 2 (0.4) | 5 (0.9) | 7 (1.3) |
| Permanent pacemaker | 2 (0.4) | 3 (0.6) | 20 (3.7) | 40 (7.5) |
| Implantable cardioverter-defibrillator | 1 (0.2) | 3 (0.6) | 4 (0.8) | 13 (2.4) |
| All-cause death | 18 (3.4) | 62 (11.5) | 108 (20.1) | 211 (39.3) |
*End of study was 31 December 2018.
†Atrial fibrillation (AF) and infective endocarditis (IE) incidences were based on patients without baseline AF (n=248) or IE (n=466) during open isolated tricuspid valve surgery (TVSx) admission.